teniposide
Term · Oncology and biomedicine · MLC-T-ONC-008587
An anticancer drug that is a podophyllotoxin derivative and belongs to the family of drugs called mitotic inhibitors.
A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle.
| Identifier | MLC-T-ONC-008587 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | EPT |
| Synonyms | Thenvlidene-Lignan-P; VM26; Thenylidene-Lignan-P |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-008587",
"term": "teniposide",
"field": "Oncology and biomedicine",
"definitions": [
"An anticancer drug that is a podophyllotoxin derivative and belongs to the family of drugs called mitotic inhibitors.",
"A semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle."
],
"abbreviation": "EPT",
"synonyms": [
"Thenvlidene-Lignan-P",
"VM26",
"Thenylidene-Lignan-P"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/teniposide/"
}
Record 16,140 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.